Pharma

NMPA approval of Enstilar® marks a key expansion for LEO Pharma in China, bringing a widely used topical psoriasis treatment to an estimated 6.5 million patients amid growing demand for innovative dermatology care.

The event brings together industry leaders in Munich to explore how quality functions are evolving into strategic, risk-based and digitally enabled systems in response to increasing regulatory complexity and innovation in pharmaceuticals and biotechnology.

Collaboration aims to develop species-specific binders to accelerate research and improve control of zoonotic diseases.

From AI-enabled GPCR discovery to partnership-driven growth, Nxera is redefining how medicines are built and commercialised.

Tinlarebant becomes the first therapy to show clinical benefit in a pivotal global trial, reducing retinal lesion growth by 36% and paving the way for a planned FDA filing in 2026.

Long-term APEX results reinforce TREMFYA® as the only IL-23 inhibitor proven to slow structural joint damage in psoriatic arthritis.